We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Indianapolis, IN based Eli Lilly and Company (LLY - Free Report) , is a global healthcare company with core products in a number of primary-care pharmaceutical markets. Lilly generates revenues from its pharmaceutical product and animal health segments.
The company’s portfolio includes Zyprexa (schizophrenia and bipolar disorder), Gemzar (pancreatic cancer), Evista (osteoporosis), Cymbalta (depression), Cialis (erectile dysfunction), Strattera (attention deficit hyperactivity disorder - ADHD), Erbitux (cancer) and Alimta (chemotherapy). Lilly also has a strong presence in the diabetes market. However, many of its key products like Cymbalta and Alimta are facing generic competition. The company also has some new products like Trulicity, Cyramza and Taltz in its portfolio which have started contributing to revenues.
Lilly’s earnings performance has been mixed with earnings surpassing expectations in two of the last four quarters, while missing in the other two, bringing the average negative surprise to 2.05%.
Currently, Lilly has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Miss: Lilly missed on fourth quarter earnings. The company reported EPS of 95 cents while our consensus called for EPS of 99 cents.
Revenues Miss: Revenues, however, were above expectations. Lilly posted revenues of $5.76 billion, compared to our consensus estimate of $5.55 billion.
2017 Outlook: The company expects 2017 revenues in the range of $21.8 billion – $22.3 billion, consistent with the guidance provide earlier in Dec 2016. Lilly continues to expect earnings per share in the range of 4.05 to $4.15. The Zacks Consensus Estimate for earnings and revenues is $4.10 per share and $21.96 billion, respectively.
Check back later for our full write up on this Lilly earnings report later!
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Lilly (LLY) Q4 Earnings Miss, Revenues Beat
Indianapolis, IN based Eli Lilly and Company (LLY - Free Report) , is a global healthcare company with core products in a number of primary-care pharmaceutical markets. Lilly generates revenues from its pharmaceutical product and animal health segments.
The company’s portfolio includes Zyprexa (schizophrenia and bipolar disorder), Gemzar (pancreatic cancer), Evista (osteoporosis), Cymbalta (depression), Cialis (erectile dysfunction), Strattera (attention deficit hyperactivity disorder - ADHD), Erbitux (cancer) and Alimta (chemotherapy). Lilly also has a strong presence in the diabetes market. However, many of its key products like Cymbalta and Alimta are facing generic competition. The company also has some new products like Trulicity, Cyramza and Taltz in its portfolio which have started contributing to revenues.
Lilly’s earnings performance has been mixed with earnings surpassing expectations in two of the last four quarters, while missing in the other two, bringing the average negative surprise to 2.05%.
Currently, Lilly has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Miss: Lilly missed on fourth quarter earnings. The company reported EPS of 95 cents while our consensus called for EPS of 99 cents.
Revenues Miss: Revenues, however, were above expectations. Lilly posted revenues of $5.76 billion, compared to our consensus estimate of $5.55 billion.
2017 Outlook: The company expects 2017 revenues in the range of $21.8 billion – $22.3 billion, consistent with the guidance provide earlier in Dec 2016. Lilly continues to expect earnings per share in the range of 4.05 to $4.15. The Zacks Consensus Estimate for earnings and revenues is $4.10 per share and $21.96 billion, respectively.
Eli Lilly and Company Price and Consensus
Eli Lilly and Company Price and Consensus | Eli Lilly and Company Quote
Check back later for our full write up on this Lilly earnings report later!
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>